Literature DB >> 33569630

The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC.

Vladimír Koucký1,2, Kamila Hladíková3, Eliška Táborská3, Jan Bouček4, Marek Grega5, Radek Špíšek3, Anna Fialová6.   

Abstract

Plasmacytoid dendritic cells (pDCs) are the most potent type I interferon-producing cells and play an important role in antiviral immunity. Tumor-infiltrating pDCs were shown to be predominantly pro-tumorigenic, with reduced ability to produce interferon alpha (IFNα) and confirmed capacity to prime regulatory T cells (Tregs) by the ICOS/ICOS-L pathway. Because a significant number of HNSCCs are induced by human papillomaviruses and show markedly different immune profiles than non-virally induced tumors, we compared the phenotype and functional capacity of HNSCC-infiltrating pDCs to the HPV status of the tumor. We observed a reduced capacity of pDCs to produce IFNα upon toll-like receptor activation in HPV-negative samples and a rather uncompromised functionality in HPV-associated tumors. Additionally, supernatants from non-virally induced but not HPV-associated tumor cell suspensions significantly inhibited IFNα production by peripheral blood-derived pDCs. We identified IL-10 and TNFα as the soluble pDC-suppressive factors with the highest variability between HPV-negative and HPV-positive tumor-derived supernatants. Additionally, we observed a positive correlation of tumor-infiltrating pDCs with Tregs in HPV-negative samples but not in virally induced tumors. Overall, our study indicates that the immunosuppressive cytokine milieu rich in IL-10 and TNFα in HPV-negative but not in HPV-positive HNSCC significantly affects the functional capacity of tumor-infiltrating pDCs, and such dysfunctional pDCs may further support the immunosuppressive tumor microenvironment by promoting the expansion of Tregs in the tumor tissue.

Entities:  

Keywords:  Head and neck cancer; Human papillomavirus; Interferon alpha; Plasmacytoid dendritic cells

Year:  2021        PMID: 33569630     DOI: 10.1007/s00262-021-02874-y

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

2.  p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency.

Authors:  Adel K El-Naggar; William H Westra
Journal:  Head Neck       Date:  2011-12-16       Impact factor: 3.147

3.  Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck.

Authors:  J Mork; A K Lie; E Glattre; G Hallmans; E Jellum; P Koskela; B Møller; E Pukkala; J T Schiller; L Youngman; M Lehtinen; J Dillner
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

Review 4.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

5.  The head and neck cancer immune landscape and its immunotherapeutic implications.

Authors:  Rajarsi Mandal; Yasin Şenbabaoğlu; Alexis Desrichard; Jonathan J Havel; Martin G Dalin; Nadeem Riaz; Ken-Wing Lee; Ian Ganly; A Ari Hakimi; Timothy A Chan; Luc Gt Morris
Journal:  JCI Insight       Date:  2016-10-20

6.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

Authors:  Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison
Journal:  J Natl Cancer Inst       Date:  2008-02-12       Impact factor: 13.506

7.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.

Authors:  Simona Partlová; Jan Bouček; Kamila Kloudová; Eva Lukešová; Michal Zábrodský; Marek Grega; Jitka Fučíková; Iva Truxová; Ruth Tachezy; Radek Špíšek; Anna Fialová
Journal:  Oncoimmunology       Date:  2015-01-30       Impact factor: 8.110

9.  Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Authors:  Ranee Mehra; Tanguy Y Seiwert; Shilpa Gupta; Jared Weiss; Iris Gluck; Joseph P Eder; Barbara Burtness; Makoto Tahara; Bhumsuk Keam; Hyunseok Kang; Kei Muro; Ravit Geva; Hyun Cheol Chung; Chia-Chi Lin; Deepti Aurora-Garg; Archana Ray; Kumudu Pathiraja; Jonathan Cheng; Laura Q M Chow; Robert Haddad
Journal:  Br J Cancer       Date:  2018-06-29       Impact factor: 7.640

Review 10.  Toxicity Reduction in the Treatment of HPV Positive Oropharyngeal Cancer: Emerging Combined Modality Approaches.

Authors:  Sarah Deschuymer; Hisham Mehanna; Sandra Nuyts
Journal:  Front Oncol       Date:  2018-10-09       Impact factor: 6.244

View more
  3 in total

Review 1.  The interplay of cytokine signaling and non-coding RNAs in head and neck squamous cell carcinoma pathobiology.

Authors:  Vivek Sharma
Journal:  Mol Biol Rep       Date:  2022-07-24       Impact factor: 2.742

Review 2.  Type I Interferon Production of Plasmacytoid Dendritic Cells under Control.

Authors:  Dóra Bencze; Tünde Fekete; Kitti Pázmándi
Journal:  Int J Mol Sci       Date:  2021-04-18       Impact factor: 5.923

Review 3.  The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications.

Authors:  Steven F Powell; Lexi Vu; William C Spanos; Dohun Pyeon
Journal:  Cancers (Basel)       Date:  2021-10-17       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.